This product sold out in record time and demand is still growing. To ensure you get your hands on it, we recommend pre-ordering now – once stock is back in stock, it may run out again within a few days. Expected restocking: 19.10.
FOXO4-DRI is a synthetic peptide designed to selectively target senescent cells. Scientific research is focusing on its potential to eliminate cells in the stage of cellular senescence without affecting healthy cells.
Concentration (test)
Unspecified
Packaging
Glass bottle with sterile cap
Storage
2–8 °C, away from light
Molecular formula
Unspecified
Molecular weight
Unspecified
Other names
FOXO4-related D-retro-inverso peptide
- selective targeting of senescent cells,
- restoration of tissue regeneration,
- research in the field of aging and longevity,
- supporting the elimination of cells with damaged DNA cycle,
- increasing vitality and metabolic balance (in models).
This professional text is for educational and research purposes only. It does not constitute a recommendation for human use.
What is FOXO4-DRI?
FOXO4-DRI is a peptide inhibitor that selectively interferes with the interaction between the FOXO4 protein and p53. This interaction plays a key role in the survival of senescent cells – cells that have lost the ability to divide but remain metabolically active and often produce inflammatory cytokines. By interrupting this signaling, senescent cells undergo apoptosis in experimental conditions without harming healthy tissues.
How does FOXO4-DRI work?
The peptide is designed as a D-retro-inverso version of a fragment of the FOXO4 protein. This version resists proteolytic degradation and is more stable in the cell environment. By blocking the binding of FOXO4 to p53, it prevents signals that would otherwise keep senescent cells alive. In this way, FOXO4-DRI enables their apoptosis (programmed cell death) and potentially promotes tissue regeneration by removing these damaged cells.
Effects studied
- Reduction in the number of senescent cells in aging mice.
- Improving physical performance and vitality in model organisms.
- Potential application in the field of regenerative medicine.
- Reduction of inflammatory markers associated with aging.
- Supporting research in the field of neurodegenerative diseases.
Dosage in studies
The data below are from preclinical models and do not constitute a recommended dosage.
-
Dose: 5–10 mg/kg
-
Form of submission: subcutaneously or intramuscularly
-
Frequency: 2× per week
-
Duration: 3–4 weeks
This text does not represent medical advice and is not intended to serve as a dosage guide for humans.
Possible side effects
- Fatigue or weakness (seen in animals).
- Potential inflammatory reactions at the injection site.
- Insufficiently researched effects of long-term use.
- Possible impact on the regeneration of healthy cells at higher doses.
Resources
- Baar et al., Cell, 2017 – Clearance of senescent cells by FOXO4-DRI peptide
- National Institutes of Health – FOXO4-p53 interaction research
- PubMed ID: 28283057
All information provided is for research and educational purposes only. It is not an approved product for human use.
Sale
